Teratogenicity of antiepileptic drugs: Role of drug metabolism and pharmacogenomics

Acta Neurologica Scandinavica

Volumn 116, Issue 1, 2007, Pages 65-71

  Sankar, R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

Antiepileptic drug; Drug metabolism; Fetal malformation; Pharmacogenomics; Pregnancy; Teratogenicity

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450 ISOENZYME; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

BIOINFORMATICS; BIRTH DEFECT; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; EPILEPSY; GENETIC POLYMORPHISM; GENETIC SCREENING; HUMAN; PHARMACOGENOMICS; PHENOTYPE; PREGNANCY OUTCOME; REVIEW; SCREENING TEST; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; CYTOCHROME P-450 ENZYME SYSTEM; EPILEPSY; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 34250837645     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2007.00830.x     Document Type: Review

References (36)

1. Morrow J, Russell A, Guthrie E et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006 77 : 193 8.
2. Cunnington M, Tennis P International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005 64 : 955 60.
3. Sabers A, Dam M, A-Rogvi-Hansen B et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004 109 : 9 13.
4. Harden CL. Do the results of pregnancy registries contradict one another Epilepsy Curr 2006 6 : 73 5.
5. Amicarelli F, Tiboni GM, Colafarina S et al. Antioxidant and GSH-related enzyme response to a single teratogenic exposure to the anticonvulsant phenytoin: temporospatial evaluation. Teratology 2000 62 : 100 7.
6. Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ. Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Arch Biochem Biophys 1997 337 : 275 83.
7. Martz F, Failinger C III., Blake DA. Phenytoin teratogenesis: correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue. J Pharmacol Exp Ther 1977 203 : 231 9.
8. Buehler BA, Delimont D, van Waes M, Finnell RH. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 1990 322 : 1567 72.
9. Robbins DK, Wedlund PJ, Kuhn R, Baumann RJ, Levy RH, Chang SL. Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine. Br J Clin Pharmacol 1990 29 : 759 62.
10. Magdalou J, Herber R, Bidault R, Siest G. In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J Pharmacol Exp Ther 1992 260 : 1166 73.
11. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002 43 (Suppl. 3 53 9.
12. Kingsley E, Gray P, Tolman KG, Tweedale R. The toxicity of metabolites of sodium valproate in cultured hepatocytes. J Clin Pharmacol 1983 23 : 178 85.
13. Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984 4 : 1143 52.
14. Granneman GR, Wang SI, Kesterson JW, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism. Hepatology 1984 4 : 1153 8.
15. Anderson GD, Acheampong AA, Wilensky AJ, Levy RH. Effect of valproate dose on formation of hepatotoxic metabolites. Epilepsia 1992 33 : 736 42.
16. Levy RH, Rettenmeier AW, Anderson GD et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990 48 : 225 35.
17. Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 1997 283 : 698 703.
18. Kultima K, Nystrom AM, Scholz B, Gustafson AL, Dencker L, Stigson M. Valproic acid teratogenicity: a toxicogenomics approach. Environ Health Perspect 2004 112 : 1225 35.
19. Eikel D, Lampen A, Nau H. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol 2006 19 : 272 8.
20. Lampen A, Siehler S, Ellerbeck U, Gottlicher M, Nau H. New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta). Toxicol Appl Pharmacol 1999 160 : 238 49.
21. Lampen A, Carlberg C, Nau H. Peroxisome proliferator-activated receptor delta is a specific sensor for teratogenic valproic acid derivatives. Eur J Pharmacol 2001 431 : 25 33.
22. Kaneko S, Otani K, Fukushima Y et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988 29 : 459 67.
23. Lindhout D, Meinardi H, Meijer J, Nau H. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992 42 (Suppl. 5 94 110.
24. Kaneko S, Battino D, Andermann E et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999 33 : 145 58.
25. Holmes LB, Harvey EA, Coull BA et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001 344 : 1132 8.
26. Finnell RH, Buehler BA, Kerr BM, Ager PL, Levy RH. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology 1992 42 (Suppl. 5 25 31.
27. Finnell RH, Kerr BM, van Waes M, Steward RL, Levy RH. Protection from phenytoin-induced congenital malformations by coadministration of the antiepileptic drug stiripentol in a mouse model. Epilepsia 1994 35 : 141 8.
28. Finnell RH, Bennett GD, Mather GG, Wlodarczyk B, Bajpai M, Levy RH. Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model. Reprod Toxicol 1999 13 : 85 91.
29. Finnell RH, Bennett GD, Slattery JT, Amore BM, Bajpai M, Levy RH. Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Teratology 1995 52 : 324 32.
30. Kurahashi N, Sata F, Kasai S et al. Maternal genetic polymorphisms in CYP1A1, GSTM1 and GSTT1 and the risk of hypospadias. Mol Hum Reprod 2005 11 : 93 8.
31. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996 75 : 517 20.
32. Glauser TA. Idiosyncratic reactions: new methods of identifying high-risk patients. Epilepsia 2000 41 (Suppl. 8) : S16 29.
33. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006 16 : 297 306.
34. Lewis DP, van Dyke DC, Stumbo PJ, Berg MJ. Drug and environmental factors associated with adverse pregnancy outcomes. Part II: Improvement with folic acid. Ann Pharmacother 1998 32 : 947 61.
35. van Dyke DC, Ellingrod VL, Berg MJ, Niebyl JR, Sherbondy AL, Trembath DG. Pharmacogenetic screening for susceptibility to fetal malformations in women. Ann Pharmacother 2000 34 : 639 45.
36. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004 45 : 737 44.